Tuesday, April 20, 2021 1:55:22 PM
Sharing "John's" post from another site:
For any “Newcomers” as always my opinion only. Bucillamine is being touted as a “Covid play” but actually it represents an “Oral Treatment Therapy” for ALL RESPIRATORY DISEASES including Covid…The reason RVVTF researched BUCI as a Covid treatment vs – let’s say Emphysema -- is because Covid is the World’s #1 health concern now… So how much attention from Politicians – Public – Big Pharma – Investment Banking / Financial Support & the Backlogged FDA do you think Revive / Buci would get vs Emphysema ? “Little to None most likely.” Buci vs Covid is the– highest profile - least expensive - easiest path to FDA approval & onto the market thus generating revenue…
There are currently only 3 COVID THERAPUTIC DRUGS APPROVED for use in the WORLD. The only one approved at this time in the US is = Remdesivir which is administered intravenously...FDA EUA has been granted for the use of Casirivimab & Imdevimab taken together + intravenously to combat mild /moderate Covid symptoms. In December 2020 Bamlanivimab was also awarded EUA for treatment of mild / moderate Covid complications - again through INJECTION.
Currently NAC / N-Acetyl Cysteine (which helps the body build antioxidants) is the #1 used therapeutic for respiratory illness & is in Phase 4 w/t FDA as a Covid therapeutic treatment.
Medical studies have shown Buci to be 16X more effective vs NAC w/no lingering side effects in treating lung complications…NAC is CURRENTLY being used to TREAT THE FOLLOWING =: Acetaminophen overdose – Chronic bronchitis – Protect liver – Repair kidney damage – Neurologic damage – Help in prevention of colon cancer – Asthma – COPD – Emphysema – Lung Cancer – Cystic Fibrosis – Pneumonia – Pleural Effusion. There is now ON GOING RESEARCH with NAC to treat: Infertility – Flu – Influenza - HIV – High Cholesterol – Some Eye Conditions - AND COVID… If Revive/ Buci is approved by the FDA it will be the 1st ORAL THERAPUTIC TABLET to be administered in the fight against Covid with POSSIBLE treatment implications for ALL Respiratory Diseases. Even if there was a 100% cure / vaccine for Covid which we’re finding out isn’t due mutations - side effects + a certain % of the population that refuse to be vaccinated: There will always be the Next Plague – Viral Infection – Pandemic - Mutation of Whatever to Ravage the world…Over the past 300 years 90%+ of the viral infections have affected the respiratory (Heart & Lungs) system in some form or another… Buci – if approved could literally be the 1ST Oral THERAPUTIC DRUG that replaces NAC…AT current Share Price of = 0.35 Cents a share my opinion is The REWARD far OUTWEIGHS the RISK over the next few weeks / months...
For any “Newcomers” as always my opinion only. Bucillamine is being touted as a “Covid play” but actually it represents an “Oral Treatment Therapy” for ALL RESPIRATORY DISEASES including Covid…The reason RVVTF researched BUCI as a Covid treatment vs – let’s say Emphysema -- is because Covid is the World’s #1 health concern now… So how much attention from Politicians – Public – Big Pharma – Investment Banking / Financial Support & the Backlogged FDA do you think Revive / Buci would get vs Emphysema ? “Little to None most likely.” Buci vs Covid is the– highest profile - least expensive - easiest path to FDA approval & onto the market thus generating revenue…
There are currently only 3 COVID THERAPUTIC DRUGS APPROVED for use in the WORLD. The only one approved at this time in the US is = Remdesivir which is administered intravenously...FDA EUA has been granted for the use of Casirivimab & Imdevimab taken together + intravenously to combat mild /moderate Covid symptoms. In December 2020 Bamlanivimab was also awarded EUA for treatment of mild / moderate Covid complications - again through INJECTION.
Currently NAC / N-Acetyl Cysteine (which helps the body build antioxidants) is the #1 used therapeutic for respiratory illness & is in Phase 4 w/t FDA as a Covid therapeutic treatment.
Medical studies have shown Buci to be 16X more effective vs NAC w/no lingering side effects in treating lung complications…NAC is CURRENTLY being used to TREAT THE FOLLOWING =: Acetaminophen overdose – Chronic bronchitis – Protect liver – Repair kidney damage – Neurologic damage – Help in prevention of colon cancer – Asthma – COPD – Emphysema – Lung Cancer – Cystic Fibrosis – Pneumonia – Pleural Effusion. There is now ON GOING RESEARCH with NAC to treat: Infertility – Flu – Influenza - HIV – High Cholesterol – Some Eye Conditions - AND COVID… If Revive/ Buci is approved by the FDA it will be the 1st ORAL THERAPUTIC TABLET to be administered in the fight against Covid with POSSIBLE treatment implications for ALL Respiratory Diseases. Even if there was a 100% cure / vaccine for Covid which we’re finding out isn’t due mutations - side effects + a certain % of the population that refuse to be vaccinated: There will always be the Next Plague – Viral Infection – Pandemic - Mutation of Whatever to Ravage the world…Over the past 300 years 90%+ of the viral infections have affected the respiratory (Heart & Lungs) system in some form or another… Buci – if approved could literally be the 1ST Oral THERAPUTIC DRUG that replaces NAC…AT current Share Price of = 0.35 Cents a share my opinion is The REWARD far OUTWEIGHS the RISK over the next few weeks / months...
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM

